Delivery Order SPE2DB20D9127-SPE2DB25FPQU9

Award Date 6/20/25
Potential Completion Date 7/14/25
Potential Value $16K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the supply of STELARA 90 MG/ML SYRINGEML, a pharmaceutical product, with a ceiling value of $16,249.95 and a completion date of June 9, 2025. DMS Pharmaceutical Group holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The $16,441.36 contract is for the delivery of STELARA 90 MG/ML SYRINGEML pharmaceutical products. DMS Pharmaceutical Group holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery orders for a wide range of pharmaceutical...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $16,441.36 contract is for the delivery of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product, with a performance period ending on April 22, 2025. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $16,441.36 contract is for the delivery of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product, with a completion date of April 25, 2025. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the DLA to issue firm...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is valued at $16,249.95 and covers the delivery of STELARA 90 MG/ML SYRINGEML, a prescription medication, by July 3, 2025. DMS Pharmaceutical Group has a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of STELARA 90 MG/ML SYRINGEML, a prescription medication, with a ceiling value of $16,441.36 and a performance period through June 3, 2025. DMS Pharmaceutical Group Inc. has also been awarded a larger $499,999,999 Indefinite Delivery Contract (IDC)...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of STELARA 90 MG/ML SYRINGEML, a prescription medication. The contract has a ceiling value of $32,499.90 and a period of performance through July 10, 2025. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC)...
This is a firm-fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is valued at $16,249.95 and will deliver the pharmaceutical product STELARA 90 MG/ML SYRINGE by July 2, 2025. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with DLA under the SPE2DB program, which enables the agency to issue delivery orders for a wide...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business located in Park Ridge, Illinois. The contract is for the delivery of STELARA 90 MG/ML SYRINGEML, with a ceiling value of $16,249.95 and a completion date of June 18, 2025. The contract is not set aside for any specific business category. DMS Pharmaceutical Group Inc. is an established pharmaceutical wholesaler that specializes in...
This is a firm fixed-price delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $16,249.95 contract was awarded on June 6, 2025 by the Defense Logistics Agency (DLA) to provide Stelara 90 mg/mL syringes. The delivery order has a completion date of June 30, 2025. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency...
  • SPE2DB20D9127
    Indefinite Delivery Contract
  • SPE2DB20D9127-SPE2DB25FPQU9
    Delivery Order

This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $16,249.95 contract is for the delivery of STELARA 90 MG/ML syringes, with a period of performance ending on July 14, 2025.

DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026. This IDC allows the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items supporting the medical supply needs of military health facilities worldwide, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables. This contract award demonstrates DMS Pharmaceutical Group's position as a crucial supplier in the federal pharmaceutical supply chain, providing direct distribution of prescription drugs and pharmacy services to Department of Defense healthcare sites.

Generated 9/19/25, 10:46 AM